5 results ยท Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine TumorNeoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, colorectal neuroendocrine tumor G1, gastric neuroendocrine tumor G1, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumorActive, not recruitingPhase 32026-10-01NCT00569127
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancerbreast adenocarcinomaActive, not recruitingPhase 32026-10-01NCT00433511
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)Neoplasms by Site, Skin and Connective Tissue Diseases, breast adenocarcinoma, breast disorder, breast neoplasm, neoplasm, skin disorderActive, not recruitingPhase 32026-10-01NCT00310180
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple MyelomaDS Stage I Multiple Myeloma; DS Stage II Multiple Myeloma; DS Stage III Multiple MyelomaActive, not recruitingPhase 32026-07-29NCT00644228
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast CancerNeoplasms by Site, Skin and Connective Tissue Diseases, breast adenocarcinoma, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinomaActive, not recruitingPhase 32026-05-06NCT02488967